Drugs /

plamotamab

Back to Drugs List

Overview

NCI Definition [1]:
A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody XmAb13676 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, XmAb13676 binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors.

Clinical Trials

View Clinical Trials for plamotamab

Plamotamab has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating plamotamab, 1 is phase 1 (1 open).

B-cell neoplasm, chronic lymphocytic leukemia/small lymphocytic lymphoma, and diffuse large B-cell lymphoma are the most common diseases being investigated in plamotamab clinical trials [2].

Drug Details

Synonyms [2]:
xmab13676
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C130050

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.